Bristol-Myers Squibb (BMY), Nektar Therapeutics (NKTR) to Evaluate Opdivo + NKTR-214 Combo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Nektar Therapeutics (NKTR) Sees Early Weakness
September 27, 2016 9:50 AM EDTNektar Therapeutics (NASDAQ: NKTR) is under heavy pressure this morning. Shares are down 8.6% on volume that is running 49x normal.
This morning, Bristol-Myers Squibb Company (NYSE: BMY) and Nektar Therapeutics... More
Nektar Therapeutics (NKTR) Offers Additional Detail on Bristol-Myers Squibb Collaboration
September 27, 2016 7:50 AM EDTNektar Therapeutics (Nasdaq: NKTR) disclosed the following in a U.S. SEC filing on Tuesday:
Item 1.01 Entry into a Material Definitive Agreement.
On September 21, 2016, Nektar Therapeutics, a Delaware corporation (Nektar), entered into a Clinical Trial Collaboration Agreement (the Agreement) with Bristol-Myers Squibb Company, a Delaware corporation (BMS), pursuant to which Nektar and BMS will collaborate to conduct Phase 1/2 clinical trials evaluating Nektars IL-2-based CD122-biased agonist, known as NKTR-214, and BMSs human monoclonal antibody that binds PD-1, known as Nivolumab, as a potential combination treatment regimen in five tumor types... More
